Clinical Trial

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 13, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Protocol Amendment History 7 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-14
notable Primary completion pushed: 2026-06 -> 2026-07-30 2026-07-14
minor Completion pushed: 2026-07 -> 2026-08-27 2026-07-14
notable Trial sites expanded: 46 -> 51 locations 2026-04-28
notable Primary completion pushed: 2026-04 -> 2026-06 2026-04-28
minor Completion pushed: 2026-05 -> 2026-07 2026-04-28
notable Trial sites expanded: 43 -> 46 locations 2026-04-01
Trial Details
NCT Number NCT06940154
Lead Sponsor Connect Biopharm LLC
Conditions COPD Acute Exacerbation
Enrollment 160 participants
Start Date 2025-08-12
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-08-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-13